secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2021-12-17T23:59:59+00:00
Accession:  0001104659-21-151192
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Pharmaceuticals appoints Kamil Ali-Jackson to board, expanding board to 10 members
--------------------------------------------------------------------------------

- Board size increased from 9 to 10; Ali-Jackson appointed effective Dec. 16, 2021, term expires at 2022 annual meeting.
- Standard non-employee director compensation: $50k annual retainer, initial option grant for 120,000 shares vesting over 3 years.
- Ali-Jackson determined independent under SEC and Nasdaq rules; no transactions requiring disclosure under Item 404(a).
- Not appointed to any standing board committee at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465921151192/0001104659-21-151192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465921151192/tm2135755d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-151192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer